Rozerem tablets 8 mg for insomnia (ramelteon)

General information on Japanese Rozerem tablets 8 mg for insomnia (ramelteon)     

Package details: 100 tablets

Manufacturer: Takeda Pharmaceutical Co. Ltd., Japan

Active ingredient: ramelteon (chemical formula C16H21NO2)

Medical effect: Rozerem tablets are effective for the treatment of insomnia.

Contraindications and precautions: do not use for the following categories of patients:

• pregnant and breastfeeding women,
• patients with liver disorder,
• patients with sleep apnea syndrome,
• patients with brain disorder.

Do not take the medicine while eating a meal or immediately after a meal. Never take the medicine if you are intending to get up in a few hours.

As this medicine may cause sleepiness, avoid driving a car, working at heights or operating dangerous machinery on mornings after taking this medicine. Avoid drinking alcohol while taking this medication.

If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Rozerem tablets 8 mg from Japan for insomnia (ramelteon)

For adults, take 1 tablet at a time, once a day, at bedtime. Even if you still remain awake, do not increase the prescribed dose at your own discretion.

How effective are Japanese Rozerem tablets 8 mg for insomnia (ramelteon)?

Rozerem tablets’ active ingredient is ramelteon, a melatonin receptor agonist. It works by binding to the MT1 and MT2 receptors in the suprachiasmatic nucleus and promoting sleep while acting upon endogenous melatonin. As a result, Rozerem tablets speed the onset of sleep and increase the total amount of sleep.

Who should take Rozerem tablets 8 mg from Japan?

Ramelteon is currently considered a unique sleep agent in its class. It does not have a direct sedating effect. Instead, Rozerem tablets naturally improve body’s circadian rhythm underlying the normal sleep-wake cycle. Studies also showed that ramelteon has no abuse liability and therefore is not even listed as a controlled substance (D. N. Neubauer. "A review of ramelteon in the treatment of sleep disorders". Neuropsychiatric Disease and Treatment. 2008, February, 4 (1): 69–79).